Revuforj targets, binds, and blocks
Revuforj is a first-of-its-kind targeted treatment called a
menin inhibitor
![See less circle]()
Revuforj is an oral, targeted medication that works differently than chemotherapy. Revuforj works by targeting a protein called
menin
to disrupt interactions with other proteins—specifically wild-type KMT2A and KMT2A fusion proteins. These
protein interactions
are responsible for driving the growth of leukemia cells in people who have acute leukemia with a KMT2A translocation or AML with an NPM1 mutation.
How menin interactions work:
Interactions between menin and certain proteins trigger the production of leukemia cells
These leukemia cells grow and multiply quickly and stop from turning into normal blood cells
Leukemia cells continue to multiply and take over the bone marrow, causing acute leukemia
How Revuforj works:
Revuforj targets and directly binds to menin to block the source of what drives your specific type of acute leukemia
Disrupting those menin interactions can help cells start to turn into normal blood cells
Without as many leukemia cells, there’s space in the bone marrow for healthy blood cells to grow
How menin interactions work:
Interactions between menin and certain proteins trigger the production of leukemia cells
These leukemia cells grow and multiply quickly and stop from turning into normal blood cells
Leukemia cells continue to multiply and take over the bone marrow, causing acute leukemia
How Revuforj works:
Revuforj targets and directly binds to menin to block the source of what drives your specific type of acute leukemia
Disrupting those menin interactions can help cells start to turn into normal blood cells
Without as many leukemia cells, there’s space in the bone marrow for healthy blood cells to grow
Revuforj will not work for everyone. Individual results may vary.
